---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-145524"
form_type: "8-K"
ticker: "STOK"
cik: "0001623526"
company_name: "Stoke Therapeutics, Inc."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:01:43.983453+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Stoke Therapeutics appoints Clare Kahn, Ph.D. to Board, increases size to ten

## Summary
- Board expanded to 10 directors; Kahn appointed as Class I director effective April 3, 2026.
- Kahn receives $45k annual cash retainer and initial option for 30,782 shares (~$724k grant-date value).
- Kahn will chair the R&D Committee and serve on the Nominating & Corporate Governance Committee.
- Kahn brings 30+ years drug development and regulatory experience from X-VAX, Pfizer, and GSK.
- Company is advancing Phase 3 study of zorevunersen for Dravet syndrome.

## SEC filing metadata
- accession: 0001193125-26-145524
- form_type: 8-K
- ticker: STOK
- cik: 0001623526
- company_name: Stoke Therapeutics, Inc.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1623526/000119312526145524/0001193125-26-145524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1623526/000119312526145524/d63742d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-145524
- JSON: https://secwatch.observer/filing/0001193125-26-145524.json
- Plain text: https://secwatch.observer/filing/0001193125-26-145524.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.